We’ve all seen it by now but great result from the #DanGerShock trial showing benefit for Impella in STEMI + cardiogenic shock

But some caution as not without a cost in terms of adverse events

AND the *effect appears to be lost on women* (and single vessel disease)

#ACC24

#milestone

Yesterday, the last patients was randomized in the #DanGerShock trial by the Copenhagen team!
Patient no. 360 💪🏻

… follow-up results expected in early 2024!

DangerShock is lead by PI Jacob E. Møller

RigsHeart 🫀🚨

Jacob Eifer Møller presenting #DangerShock results at DCS annual meeting: In patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone 🫀
#DCSårsmøde2024

DANGERSHOCK results presented at the ACC24 meeting - benefit of mechanical support of cardiogenic shock in myocardial infarction. Cardiac unloading works in cardiogenic shock and improves intermediate clinical outcomes! Full data in the NEJM.

#DanGerShock trial in perspective
⤵️ Check the video summary
Full article available at #EHJACVC doi.org/10.1093/ehjacc…

SCAI Now #ACCIC PCRonline 🫀 #EAPCI

Not the same patient, but a SCAI Shock C how would you manage❓

MCS or not.. #DanGerShock soon at #ACC24

How would ACGME pose the question❓

Allison Dupont, MD Babar Basir Timothy Henry Anna Bortnick MD, PhD, MSc Holger Thiele chief Srihari S. Naidu, MD

Inclusion going strong! #DangerShock - lots of German activity.

📍March 13, Ralph Westenfeld and his team in Düsseldorf randomized patient no 100 in Germany.

🎯 Less than 80 patients to go…

The results #Dangershock are now available! I am thrilled to have worked at one of the participating sites. This marks a significant advancement in enhancing the management of cardiogenic shock complicating a STEMI.
#ACC24
Norman Mangner

Really proud of the 🇩🇰🇩🇪 🇬🇧collaboration and findings of the DanGerShock trial - significant reduction of mortality with the use of the Impella device in cardiogenic shock patients 🫀! NEJM Abiomed RigsHeart 🫀🚨 Christian Hassager JacobEMoller 💪 PCRonline 🫀

#DanGerShock trial. LV mechanical circulatory support with #IMPELLA CP prior to PCI could improve survival rates in #STEMI complicated by Cardiogenic shock LBCT #ACC24
Given the previous neutral results with IABP in this scenario?

#Trialupdate

The #DanGershock statistical analysis plan for the main analyses just published in
AmericanHeartJ - read more below:
clinicalkey.com/#!/content/pla…

PI Professor Jacob Eifer Møller

🎯 Expected enrollment of the last patient in 2023.

We have read Dangershock trial with great interest and depth. It caught our attention that study protocol uniformly recommended P8 (higher RPM increases hemolysis, as is well known). We believe that a more tailored approach could reduce the rates of renal failure.
#impella

Clarification/updates from Jacob for those not on LinkedIn #dangershock

#ACC24 #DanGerShock
Allison Dupont, MD Sandeep Nathan, MD, MSc Mamas A. Mamas Dr Shariq Shamim Hady Lichaa, MD, FACC, FSCAI, FSVM, RPVI Pooja Swamy, MD, FACC, FSCAI Sanah Christopher Kashish Goel Sachin Goel Saraschandra Vallabhajosyula, MD MSc Dmitry Abramov Kate Kearney Katherine Kunkel, MD, MSEd

New drinking game: take a shot whenever someone mentions #DanGerSHOCK . Much deserved discussion since #ACC24 with it now being highlighted at #ARCHSymposium #ARCH2024

#CardioTwitter #CardioEd #CardioX

🚴🏼🚴🏼🚴🏼 We’re getting closer to the final inclusion; #DanGer Shock Trial…

… today, Andreas Schaefers’ team in Hannover included patient no. 300 🎉 Well done!

60 patients to go!

#DanGer Shock #impella #cardiogenicshock Syddansk Universitet OUH Odense Svendborg RigsHeart 🫀🚨
PI Prof J.E.Møller

Update on landmark DANGERShock trial by Robert W. Yeh MD.

Questions exist on gender differences seen. Much more to learn and study.

Study time period covered broad time period with broad change in technique.

Guideline change coming???

#SCAI2024

What is so special about #DanGerShock ?

🔥 10y of work 💪
➡️ International trial
✅ 13% ⬇️ all-cause mortality in 180 days using Impella vs standard care alone
➡️Still ⬆️ risk of complications in #MCS group
Someone called it a trial of the decade, is it indeed? #ACC24

Absolutely extraordinary work from the #DanGershock investigators including our own Vas Panoulas. Finally we have an intervention that unquestionably saves lives in #ACS #cardiogenicShock .
Our award winning courses teach you how to manage emergencies in #impella patients. DMs open.

#DANGERSHOCK trial
Percutaneous microaxial flow pumps can reduce all-cause mortality in AMI-CS.
- 14% risk reduction and NNT of 8. Increased risk for bleeding, limb ischemia and need for RRT #ACC24 Turkish Society of Cardiology